NCT04516954 (CPCP) is a EARLY_PHASE1 clinical trial of Convalescent COVID 19 Plasma in COVID 19, sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

Who is sponsoring NCT04516954?

NCT04516954 is sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

What drugs are being tested in NCT04516954?

Interventions in NCT04516954: Convalescent COVID 19 Plasma.

Is NCT04516954 still recruiting?

NCT04516954 is currently completed. Last updated 6 June 2024.

Last reviewed 2024-06-06 · How we verify

NCT04516954: CPCP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma for COVID-19 Patients

Completed EARLY_PHASE1 Last updated 6 June 2024

What this trial tests

EARLY_PHASE1 trial testing Convalescent COVID 19 Plasma in COVID 19 in 4 participants. Completed in 30 April 2021.

Timeline

1 August 2020

Primary endpoint
30 March 2021

30 April 2021

Quick facts

Lead sponsor	Vinmec Research Institute of Stem Cell and Gene Technology
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	1 August 2020
Primary completion	30 March 2021
Estimated completion	30 April 2021
Sites	1 location across Vietnam

Drugs / interventions tested

Convalescent COVID 19 Plasma — full drug profile →

Conditions studied

COVID 19 — all drugs for COVID 19 →

Sponsor

Vinmec Research Institute of Stem Cell and Gene Technology

Who can join

Adults 18 to 75, any sex, with COVID 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. The first phase is to test the safety of CP therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6

Verify or expand the search:

Other trials of Convalescent COVID 19 Plasma

Trials testing the same drug.

NCT04355897 — CoVID-19 Plasma in Treatment of COVID-19 Patients · EARLY_PHASE1 · completed

Other recruiting trials for COVID 19

Currently open trials in the same condition.

NCT06871293 — Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19 · NA · recruiting
NCT06599658 — COVID-19 Booster and IIV Schedule in Immunocompromised Hosts · Phase 2 · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04522076 — Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acq · active not recruiting
NCT06702540 — Bio-reconfigurable Electronic Platform for Multiplex Detection of Viral Respiratory Pathogens · active not recruiting

Other Vinmec Research Institute of Stem Cell and Gene Technology trials

Trials by the same sponsor.

NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment · Phase 1 · not yet recruiting
NCT06629324 — Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia · Phase 2 · recruiting
NCT06726538 — Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Func · Phase 1, PHASE2 · completed
NCT06027957 — CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia · Phase 1 · completed
NCT05329662 — Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04516954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vinmec Research Institute of Stem Cell and Gene Technology
Last refreshed: 6 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04516954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing